LIFEHOUSE: Description of the Tent Bucket -Immune Support (LIFEHOUSE)

October 26, 2023 updated by: Metagenics, Inc.

LIFEHOUSE: a Lifestyle Intervention and Functional Evaluation- a Health OUtcome SurvEy; Description of the Tent Bucket -Immune Support

This immune support program will be an extension to the existing LIFEHOUSE program. Essential employees in Gig Harbor, WA; Colonial Heights, VA; Lenexa, KS, and Santa Fe Springs, CA, will be offered complimentary supplementation with commercially available nutritional supplements supportive of immune health for several months. The outcome will be measured via blood parameters and questionnaire responses.

Study Overview

Status

Completed

Conditions

Detailed Description

This program, as a component of the LIFEHOUSE program, will consist of data collection during a period of supplementation with commercially available nutritional supplements supportive of immune health. Employees, in Gig Harbor, WA; Colonial Heights, VA; Lenexa, KS, and Santa Fe Springs, CA, will be offered the opportunity to participate.

The nutritional and inflammatory status will be captured via fingerstick biomarkers. Participants will receive in-home testing kits including instructions regarding the applicable fingerstick blood collections. Fingerstick testing will include 25-Hydroxy Vitamin D3 (25-OH D3) and high sensitivity c-reactive protein (hs-CRP) measurements at baseline, 1, and 2 (phase 1), or at baseline 1,2, 3, and 6 months intervals (phase 2).

Participants will also be asked to complete applicable questionnaires (QNs) electronically monthly using standard software programs for questionnaire completion.

This will include the Medical Outcome Study (MOS) Short Form (SF) -36 (baseline and monthly) and Health Status QNs including questions on compliance, wellbeing, lifestyle (exercise, shifts worked, medications and supplements, and diet) (baseline and monthly).

Study Type

Interventional

Enrollment (Actual)

7

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Washington
      • Gig Harbor, Washington, United States, 98332
        • Personalized Lifestyle Medicine Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 69 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male or Female
  • Ages 18-69, inclusive
  • Metagenics' employees in Gig Harbor, WA; Colonial Heights, VA; Lenexa, KS, and Santa Fe Springs, CA
  • General good health
  • Willing to give written informed consent to participate in the study

Exclusion Criteria:

  • An allergy to any ingredient in Vit.D3 5000 and/or Immune Active
  • A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, psychiatric, immunologic/rheumatological, or oncological/hematologic disease.
  • Hyperparathyroidism
  • Granulomatous disorders including as sarcoidosis, tuberculosis, leprosy, berylliosis, histoplasmosis, and coccidioidomycosis
  • Chronic renal insufficiency
  • Nephrolithiasis
  • Prior cancer diagnosis
  • Known infection with human immunodeficiency virus (HIV), tuberculosis (TB), or Hepatitis B or C.
  • Established psychiatric disease including moderate to severe depression, thought disorders and bipolar disorder
  • Planned use of nutritional supplements (exclusive of multiple vitamin/mineral supplements and medical foods) containing in total more than 1,000 IU Vitamin D3 and/or 10 mg Zinc
  • Use of pharmaceutical nitrates for any indication
  • Use of drugs of abuse and recreational drugs/substances (such as but not limited to opioids, cocaine, phencyclidine (PCP), and methamphetamine)
  • History of marijuana or cannabinoid abuse within 12 months prior to screening and for the duration of the study.
  • History of alcohol abuse or a diagnosis of alcoholism within 12 months prior to screening and for the duration of the study.
  • Pregnant or breastfeeding women
  • Inability to comply with study and/or follow-up visits.
  • Any concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the Principal Investigator (PI), would preclude safe participation in this study or interfere with compliance.
  • Any sound medical, psychiatric, and/or social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Immune response
This is a single-arm study. All subjects will be treated equally and will receive the same type and amount of nutritional supplements.

The subjects will receive monthly (for either 3 or 6 months):

  1. Vit.D3 5000 and Immune Active. The first phase includes 3 months of treatment and the second phase includes 6 months of treatment.
  2. An in-home Vit.D/ hs-CRP test kit and asked to self-administer a blood collection via fingerstick and return the kits for analysis within a few days.
  3. Two online questionnaires each month and asked to fill them out within a few days. It will either be the Medical Outcomes Study (MOS) Short Form (SF)-36 and the Health Status Baseline or Health Status Follow-up Questionnaire.
Other Names:
  • Questionnaires
  • Test kits- Vit.D and hs-CRP blood measurements

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of health.
Time Frame: 12 weeks (Phase 1) or up to 6 months (Phase 2)
The primary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically a marker of nutritional status (25-hydroxy Vitamin D3 (25-OH D3)) and a marker of immune balance (high sensitivity c-reactive protein (hs-CRP) in a real-world setting.
12 weeks (Phase 1) or up to 6 months (Phase 2)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of quality of life.
Time Frame: 12 weeks (Phase 1) or up to 6 months (Phase 2)
The first secondary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically upon quality of life as measured by Rand Medical Outcome Study 36-Item Short Form Survey (MOS SF-36).
12 weeks (Phase 1) or up to 6 months (Phase 2)
The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of the absence of infections.
Time Frame: 12 weeks (Phase 1) or up to 6 months (Phase 2)
The second secondary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically experience-defined events (tally of well days during assessed periods and absence of laboratory-confirmed SARS-CoV-2 and Influenza infections).
12 weeks (Phase 1) or up to 6 months (Phase 2)
The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of weight and body composition.
Time Frame: 12 weeks (Phase 1) or up to 6 months (Phase 2)
The third secondary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically in weight and body composition.
12 weeks (Phase 1) or up to 6 months (Phase 2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Josesph J Lamb, MD, Medical Director

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 22, 2021

Primary Completion (Actual)

July 31, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

January 25, 2021

First Submitted That Met QC Criteria

January 27, 2021

First Posted (Actual)

February 2, 2021

Study Record Updates

Last Update Posted (Actual)

October 30, 2023

Last Update Submitted That Met QC Criteria

October 26, 2023

Last Verified

April 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Immune Response

Clinical Trials on Vit.D3 5000 IU, Immune Active

3
Subscribe